Skip to content
OpenCapital
Get started

AnaptysBio, Inc. ANAB Increase (Decrease) in Contract with Customer, Asset

Increase (Decrease) in Contract with Customer, Asset at other companies

Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
——

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.73B+180%
Enterprise value$1.48B+176%
P/S7.4×+1.9×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity0×-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerAsset.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s increase (decrease) in contract with customer, asset.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AnaptysBio, Inc.'s increase (decrease) in contract with customer, asset?
AnaptysBio, Inc. (ANAB) reported increase (decrease) in contract with customer, asset of -$8.1M in Q1 2026.
How has AnaptysBio, Inc.'s increase (decrease) in contract with customer, asset changed year-over-year?
AnaptysBio, Inc.'s increase (decrease) in contract with customer, asset increased by 64.6% year-over-year, from -$22.88M to -$8.1M.
What is the long-term trend for AnaptysBio, Inc.'s increase (decrease) in contract with customer, asset?
Over 2 years (2022 to 2024), AnaptysBio, Inc.'s increase (decrease) in contract with customer, asset has grown at a 690.3% compound annual growth rate (CAGR), from $543K to $33.91M.